ARTICLE | Clinical News
Tocosol: Phase IIa data
June 14, 2004 7:00 AM UTC
In a Phase IIa trial in 52 patients, 3 of 51 evaluable patients had complete responses and 17 had partial responses. Median time to disease progression was 24 weeks and the median survival has not yet...